-
Key Brands
-
Statistics
-
Revenue
-
Contribution
-
Analysis
| Brand | Therapeutic category |
|---|---|
| Circadin | Hormonal hypnotic sedative |
| Eltroxin | Thyroid hormone replacement |
| Maltofer | Iron supplement |
| Marcaine | Regional and spinal anaesthetic |
| Xylocaine | Regional anaesthetic |
0
Products
Launched
Launched
(2021: 2)
Product
Recalls
Recalls
(2021: Nil)
0 %
Average Staff
Turnover
Turnover
(2021: 8%)
Work-related
Facilities
Facilities
(2021: Nil)
435
Sales
Representatives
Representatives
(2021: 74)
200
Permanent
Employees
Employees
(June 2021: 538)
| Revenue | 2022 R’million | 2021 (CER) R’million | Change % |
|---|---|---|---|
| Commercial Pharmaceuticals | 5 103 | 4 680 | 9 |
| Regional Brands | 4 464 | 3 955 | 13 |
| Sterile Focus Brands | 643 | 725 | (11) |
| Manufacturing – FDF | 596 | 532 | 12 |
| Total | 5 703 | 5 212 | 9 |
Note: Commercial Pharmaceuticals revenue is by customer geography and manufacturing revenue is by place of manufacture.
Contribution to Group revenue (%)
- Rest of Group 85
- Australasia 15
Revenue by segment (%)
- Regional Brands 79
- Sterile Focus Brands 11
- Manufacturing - FDF 10
- The Australia and New Zealand OTC market was valued at AUD4,5 billion in June 2022 and grew 12,9% driven by recovery of various therapeutic segments specifically the Cough/Cold/Flu and related segments as a result of stay-at-home COVID-19 treatments and severe cold and flu season.
- The total pharmaceutical segment excluding the grocery channel grew 9,2% June 2022.
Source: IQVIA June 2022
